Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampicin on HRS-5041 PK in Healthy Subjects
NCT07014488Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS-5041 in prostate cancer (PCa), sponsored by Hengrui. Primary endpoints: Area Under the Curve from time 0 to time t, Area Under the Curve from time 0 to infinity and 1 more. Started Jun 2025; status: completed.
02
Drugs
HRS-5041
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07014488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014488.